Artigo de periodico

Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival (2018)

• Authors:
  • Fernandes, Jaqueline Cristina
  • Alves, Ana Paula Nunes Rodrigues
  • Silva, Juan Luiz Coelho da
  • Ribeiro, Renata Scopim
  • Fenerich, Bruna Alves
  • Simões, Belinda Pinto
  • Rego, Eduardo Magalhães
  • Machado Neto, João Agostinho
  • Traina, Fabíola
• USP affiliated authors: MACHADO NETO, JOÃO AGOSTINHO - ICB ; TRAINA, FABÍOLA - FMRP
• Unidades: ICB; FMRP
• DOI: 10.1186/s41241-018-0058-8
• Subjects: CICLINA D1; LEUCEMIA; PROGNÓSTICO; LINFÓCITOS; CICLINA D1; LINFÓCITOS; MEDULA ÓSSEA; EXPRESSÃO GÊNICA; REAÇÃO EM CADEIA POR POLIMERASE
• Agências de fomento:
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
  • Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
    Processo FAPESP: 2013/08135-2
• Language: Inglês
• Imprenta:
  • Publisher: BioMed Central Ltd.
  • Place of publication: London
  • Date published: 2018
• Source:
  • Título do periódico: Applied Cancer Research
  • ISSN: 1980-5578
  • Volume/Número/Paginação/Ano: v. 38, art. 7, 4 p, 2018

Informações sobre o DOI: 10.1186/s41241-018-0058-8 (Fonte: oaDOI API)
• Este periódico é de acesso aberto
• Este artigo é de acesso aberto
• URL de acesso aberto
• Cor do Acesso Aberto: gold
• Licença: cc-by

---

How to cite

A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas

• ABNT

  FERNANDES, Jaqueline Cristina; ALVES, Ana Paula Nunes Rodrigues; SILVA, Juan Luiz Coelho da; et al. Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival. Applied Cancer Research, London, BioMed Central Ltd., v. 38, 2018. Disponível em: < https://doi.org/10.1186/s41241-018-0058-8 > DOI: 10.1186/s41241-018-0058-8.

• APA

  Fernandes, J. C., Alves, A. P. N. R., Silva, J. L. C. da, Ribeiro, R. S., Fenerich, B. A., Simões, B. P., et al. (2018). Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival. Applied Cancer Research, 38. doi:10.1186/s41241-018-0058-8

• NLM

  Fernandes JC, Alves APNR, Silva JLC da, Ribeiro RS, Fenerich BA, Simões BP, Rego EM, Machado Neto JA, Traina F. Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival [Internet]. Applied Cancer Research. 2018 ; 38Available from: https://doi.org/10.1186/s41241-018-0058-8

• Vancouver

  Fernandes JC, Alves APNR, Silva JLC da, Ribeiro RS, Fenerich BA, Simões BP, Rego EM, Machado Neto JA, Traina F. Increased levels of cyclin D1 negatively impacts on acute lymphoblastic leukemia overall survival [Internet]. Applied Cancer Research. 2018 ; 38Available from: https://doi.org/10.1186/s41241-018-0058-8

Referências citadas na obra

Paul S, Kantarjian H, Jabbour EJ. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2016;91(11):1645–66.
Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030–43.
Hydbring P, Malumbres M, Sicinski P. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 2016;17(5):280–92.
Asghar U, Witkiewicz AK, Turner NC, Knudsen ES. The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov. 2015;14(2):130–46.
Casimiro MC, Velasco-Velázquez M, Aguirre-Alvarado C, Pestell RG. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert Opin Investig Drugs. 2014;23(3):295–304.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 2001;25(4):402–8.
Wang CX, Wang X, Liu HB, Zhou ZH. Aberrant DNA methylation and epigenetic inactivation of hMSH2 decrease overall survival of acute lymphoblastic leukemia patients via modulating cell cycle and apoptosis. Asian Pac J Cancer Prev. 2014;15(1):355–62.
Taniguchi T, Fujita A, Takahashi S, Uchimaru K, Yoshikawa M, Asano S, et al. Cyclin D1 overexpression detected by a simple competitive reverse transcription-polymerase chain reaction assay for lymphoid malignancies. Jpn J Cancer Res. 1998;89(2):159–66.
Aref S, Mabed M, El-Sherbiny M, Selim T, Metwaly A. Cyclin D1 expression in acute leukemia. Hematology. 2006;11(1):31–4.
Elsayed GM, Ismail MM, Moneer MM. Expression of P-glycoprotein, Cyclin D1 and Ki-67 in acute lymphoblastic leukemia: relation with induction chemotherapy and overall survival. Indian J Hematol Blood Transfus. 2011;27(3):157–63.
Sauerbrey A, Häfer R, Zintl F, Volm M. Analysis of cyclin D1 in de novo and relapsed childhood acute lymphoblastic leukemia. Anticancer Res. 1999;19(1B):645–9.
Volm M, Koomägi R, Stammler G, Rittgen W, Zintl F, Sauerbrey A. Prognostic implications of cyclins (D1, E, A), cyclin-dependent kinases (CDK2, CDK4) and tumor-suppressor genes (pRB, p16INK4A) in childhood acute lymphoblastic leukemia. Int J Cancer. 1997;74(5):508–12.
Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112(13):4808–17.
Afar DE, McLaughlin J, Sherr CJ, Witte ON, Roussel MF. Signaling by ABL oncogenes through cyclin D1. Proc Natl Acad Sci U S A. 1995;92(21):9540–4.
Liu JH, Yen CC, Lin YC, Gau JP, Yang MH, Chao TC, et al. Overexpression of cyclin D1 in accelerated-phase chronic myeloid leukemia. Leuk Lymphoma. 2004;45(12):2419–25.
Gleissner B, Gokbuget N, Bartram CR, Janssen B, Rieder H, Janssen JW, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99(5):1536–43.
Short NJ, Kantarjian H, Jabbour E, Ravandi F. Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia? Best Pract Res Clin Haematol. 2017;30(3):193–200.

Últimas obras dos mesmos autores vinculados com a USP cadastradas na BDPI:

• De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes
• IRAK1 expression in bone marrow cells does not impact patient outcomes in myelodysplastic syndromes. [Carta]
• Stathmin 1 expression in plasma cell neoplasms. [Carta]
• DNMT3A is highly expressed in bone marrow cells from acute myeloid leukemia patients
• A ativação da via IGF1R prediz prognóstico e representa uma estratégia terapêutica em leucemia mieloide aguda
• The pharmacological IGF1R-IRS1/2 inhibitor NT157 presents multiple anti-neoplastic effects in myeloproliferative neoplasms
• Stathmin 1 is highly expressed and is inhibited by paclitaxel in acute lymphoblastic leukemia cells
• Stathmin 1 é altamente expressa em leucemia promielocítica aguda e a dinâmica dos microtúbulos é um alvo potencial para células PML-RAR resistentes ao atra
• High cyclin D1 expression negatively impacts adult acute lymphoblastic leukemia outcomes
• Metformin reduces tumor burden and splenomegaly in JAK2V617F murine models